Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;103(9):e404-e407.
doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Ibrahim Aldoss  1 , Dongyun Yang  2 , Ahmed Aribi  1 , Haris Ali  1 , Karamjeet Sandhu  1 , Monzr M Al Malki  1 , Matthew Mei  1 , Amandeep Salhotra  1 , Samer Khaled  1 , Ryotaro Nakamura  1 , David Snyder  1 , Margaret O'Donnell  1 , Anthony S Stein  1 , Stephen J Forman  1 , Guido Marcucci  1 , Vinod Pullarkat  3
Affiliations

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Ibrahim Aldoss et al. Haematologica. 2018 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival of refractory/relapsed acute myeloid leukemia (AML) after hypomethylating agent and venetoclax therapy. (A) Overall survival and (B) leukemia-free survival (LFS).
See this image and copyright information in PMC

References

    1. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106–1117. - PMC - PubMed
    1. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409. - PubMed
    1. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311–22. - PMC - PubMed
    1. Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341. - PMC - PubMed
    1. Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657–1665. - PMC - PubMed

MeSH terms